Introduction
Tamoxifen has proven to be one of the most successful agents in the management of estrogen receptor (ER)positive breast cancers, and it has been a mainstay of endocrine therapy for breast cancer over the last 30 years. Large studies have shown its value in the improvement of survival in early breast cancer (Osborne, 1998; EBCTCG, 2005) , as well as an improvement in the quality of life for patients with metastatic disease (Jaiyesimi et al., 1995) . However, despite the remarkable benefits of using ER-targeted therapies, including selective ER modulators (SERMs) such as tamoxifen in the ca 70% of women with hormone-sensitive breast cancers expressing ERs, many will eventually experience disease progression, owing to the development of resistance to the therapy. The mechanisms that underlie endocrine resistance are complex and are not fully understood, despite significant advances in defining some of the players involved (Creighton et al., 2006; Green and Carroll, 2007; Arpino et al., 2008; Massarweh et al., 2008) .
In a previous study, based on genome-wide gene expression analyses in human breast tumors and in ER-positive breast cancer cells, we found 14-3-3z (also known as YWHAZ) to be upregulated by tamoxifen and observed a poor clinical outcome on tamoxifen treatment for patients with high levels of 14-3-3z in their breast tumors (Frasor et al., 2006) . This correlation between overexpression of 14-3-3z and early onset of recurrence was also observed by us in data from other large microarray gene expression studies, implying 14-3-3z to be a marker of poor prognosis in women with ER-positive breast cancers (Bergamaschi et al., 2009 ). 14-3-3z is a member of the highly conserved family of seven 14-3-3 proteins, all encoded by different genes (Tzivion et al., 2006) . 14-3-3z serves as a pivotal factor that binds and stabilizes key proteins involved in signal transduction, cell proliferation and apoptosis (Ando et al., 2004; Costa, 2005) , including EGFR, HER2, PKC, b-catenin and RAF-1 (McPherson et al., 1999; Oksvold et al., 2004; Filipowicz et al., 2008) .
In view of the very detrimental role of 14-3-3z in promoting cancer cell survival and endocrine resistance, we were interested in understanding how 14-3-3z is regulated, and in particular, how cellular levels of 14-3-3z might be downregulated to enhance responsiveness to endocrine therapies. As growing evidence links micro-RNAs (miRs) to the control of many crucial processes in cancer, including proliferation, differentiation and apoptosis (Croce, 2009) , we have herein explored the involvement of miRs in the regulation of 14-3-3z. The great importance of miRs is underscored by the fact that they are estimated to have roles in regulating the expression of more than one-third of all human genes. miRs, which are small, ca 22-nucleotide RNA sequences, bind principally to the 3 0 -untranslated region (UTR) region of mRNAs of protein-coding target genes to direct their repression by destabilizing target mRNAs and decreasing mRNA translational efficiency (Bartel, 2004; Harfe, 2005; Guo et al., 2010) .
In the present study, to investigate the mechanism underlying tamoxifen upregulation of 14-3-3z, we first identified, by bioinformatic analysis, potential miRs that might regulate 14-3-3z, and then went on to show tamoxifen downregulation of miR-451 and to delineate the role of miR-451 in regulating 14-3-3z and its impact on the aggressiveness, cell survival properties and endocrine sensitivity of ER-positive breast cancer cells. The findings suggest that increasing the cellular level of miR-451 might be a useful therapeutic approach for reversing endocrine resistance and enhancing the efficacy of endocrine therapies in the >40% of breast tumors that overexpress 14-3-3z.
Results
Tamoxifen downregulates miR-451 and there is an inverse relationship between miR-451 and 14-3-3z levels Although we have reported 14-3-3z to be upregulated by the antiestrogen (SERM) tamoxifen in breast cancer (Frasor et al., 2006) , the mechanism regulating tamoxifen-driven stimulation of 14-3-3z is not known. Given the growing evidence for the importance of miRNAs in regulating gene expression, we envisioned that miRNAs might have an important role in modulating 14-3-3z expression. Using two different target prediction algorithms, TargetScan (http://www.targetScan.org/) and miRanda (http://www.microrna.org/microrna/ home.do), we found nine miRNAs that were predicted by both algorithms to target 14-3-3z. From these, we chose to investigate miR-451 because it showed relatively few potential targets, and 14-3-3z was the only predicted target from the 14-3-3 family. We then examined whether tamoxifen might regulate miR-451. As shown in Figure 1a , where we monitored the effects of different ER ligands on miR-451 expression, we observed that only Tam had the ability to downregulate miR-451 and that downregulation occurred as early as 4 h, whereas the estrogen estradiol (E2), the SERM raloxifene (Ral) and the pure antiestrogen ICI182,780 Tamoxifen, miR-451 and 14-3-3f regulation A Bergamaschi and BS Katzenellenbogen (ICI, Fulvestrant) had no effect on miR-451. The downregulation of miR-451 by Tam was reversed by excess ICI, implying mediation of the Tam effect by ER. Likewise, depletion of ERa by ca 90% by cell treatment with siRNA targeting ERa (Chang et al., 2008) eliminated the downregulation of miR-451 by tamoxifen ( Figure 1a ). To further explore the regulation of miR-451 by tamoxifen, we analyzed the presence over time of RNA polymerase II (Pol II) at the transcription start site of miR-451 (transcription start site derived from the data of Welboren et al., 2009) in cells treated with control vehicle (Veh) or Tam R . Interestingly, we found that Tam treatment markedly reduced the level of Pol II at the transcription start site of miR-451 ( Figure 1b ), consistent with the downregulation of miR-451 expression we observed upon treatment with tamoxifen.
The highly conserved miR-451 gene is located on chromosome 17, only 100 bp upstream of another miR, miR-144. We therefore examined if this nearby miR-144 was also regulated by Tam or other ER ligands. As shown in Figure 1c , we observed that Tam had no effect on the expression of miR-144, indicating the selectivity of tamoxifen for miR-451 regulation.
We next examined the levels of miR-451 in parental MCF7 and in tamoxifen-resistant MCF7 (Tam R ) cells and found that parental cells expressed three-times more miR-451 than did Tam R cells (Figure 1d ), whereas Tam R cells had higher levels of 14-3-3z ( Figure 1e ), suggesting an inverse relationship between these two factors. Further, upon treatment of both MCF7 and Tam R cells with tamoxifen, we observed a timedependent decrease in miR-451 and an increase in 14-3-3z over time (Figures 1e and f) . A similar inverse relationship between miR-451 and 14-3-3z was observed in other tamoxifen-resistant MCF7 cells selected in our laboratory (data not presented).
Overexpression or knockdown of miR-451 impacts 14-3-3z, cell proliferation and colony formation, apoptosis, and sensitivity to SERMs To further investigate miR-451 regulation of 14-3-3z, we overexpressed miR-451 by transfecting pri-miRNA into MCF7 and Tam R cells and monitored mRNA and protein levels of 14-3-3z by quantitative PCR and western blot. As shown in Figures Tamoxifen, miR-451 and 14-3-3f regulation A Bergamaschi and BS Katzenellenbogen overexpression of miR-451 greatly reduced the level of 14-3-3z in both cell lines. We also examined the specificity of miR-451 action for targeting only 14-3-3z and not other 14-3-3 family members, and found that only 14-3-3z was significantly affected by expression of miR-451 ( Figure 2c ). We next examined the impact of miR-451 status on proliferation and apoptosis of breast cancer cells resistant to Tam, by either overexpressing or knocking down miR-451. As shown in Figure 3a , Tam acted as an agonist in Tam R cells, enhancing the proliferation of these cells over Veh control. Cells transfected with miR-451 showed greatly reduced proliferation and notably, this suppressive effect of miR-451 on proliferation was reversed by expression of 14-3-3z ( Figure 3a) . Also, knockdown of miR-451 (miR-451 KD) by treatment of cells with miR-451 antagomir, which suppressed endogenous miR-451 and increased 14-3-3z levels (Figure 3b ), increased cell proliferation ( Figure 3c ). To determine the impact of 14-3-3z alone on cell viability, we downregulated its expression by siRNA and observed a significant decrease in basal and tamoxifen-stimulated cell proliferation (Figure 3d ). Overexpression of miR-451, which reduced 14-3-3z without affecting ERa protein or mRNA levels ( Figure 3f ), resulted in suppression of the growth of Tam R cells in the presence of the SERMs tamoxifen or Raloxifene, or Fulvestrant (ICI 182,780) ( Figure 3e ). After overexpression of miR-451, we also observed a marked reduction in anchorage-independent colony formation of Tam R cells, that is, a significant decrease in number and size of colonies in the Veh and Tamtreated cells, suggesting a potential tumor suppressorlike activity of this miR (Figure 3g ).
To understand the basis of the reduced cell viability and colony formation in cells overexpressing miR-451, we monitored 14-3-3z, CASP7 and cleaved CASP7 protein upon Tam treatment. As seen in Figure 4a , we observed greatly reduced 14-3-3z protein levels with miR-451 overexpression, as expected, and also elevated levels of CASP7 and cleaved CASP7. When 14-3-3z was re-expressed in cells overexpressing miR-451, the CASP7 and cleaved CASP7 levels were greatly decreased, becoming comparable to the low levels seen in control cells, indicating that miR-451, by altering intracellular14-3-3z, not only inhibits proliferation as shown in Figure 3 , but also stimulates the apoptotic cascade. These changes were also reflected in the marked increase in proportion of cells in the sub-G1 phase of the cell cycle with miR-451 overexpression ( Figure 4b ). There also was a great increase in the percent of apoptotic cells, rising from 2 to 13% and from 5 to 24% in Veh-and Tam-treated cells, respectively (Figure 4b ). The proportion of cells in the sub-G1 phase of the cell cycle and the percent of apoptotic cells were significantly reduced when 14-3-3z was re-expressed in cells overexpressing miR-451 (Figures 4b and c) .
Elevated levels of miR-451 reduce the activation of growth factor receptor tyrosine kinases and protein kinases As endocrine resistance is often associated with the upregulation of growth factor receptor and protein kinase signaling, we evaluated the effects of 14-3-3z and miR-451 on the activation of some growth factor receptors and kinases. We observed a significant increase in phosphorylation of HER2, EGFR, AKT and MAPK upon 14-3-3z overexpression (Figure 5a ).
We also examined the impact of miR-451 on these receptors and downstream signaling pathways, and observed that levels of phosphoHER2 and phos-phoEGFR were greatly reduced in cells overexpressing miR-451, and pMAPK was also decreased, although only a slight reduction was observed in pAKT ( Figure 5b ).
Selective action of miR-451 on 14-3-3z controls cell proliferation
To further delineate the importance of 14-3-3z in the actions of miR-451, we used a selective 14-3-3z target protector to examine the specificity of miR-451 action. Of the 14 targets for miR-451 predicted by the TargetScan algorithm, we found 8 to be expressed in MCF7 cells. Knockdown of endogenous miR-451 increased only the level of 14-3-3z (Figure 6a ). However, with high overexpression of miR-451, 14-3-3z was (Figure 6a ). As shown in Figure 6b , in control cells, tamoxifen only upregulated 14-3-3z, and had no effect on OGT or CDKN2D. These observations suggest that OGT and CDKN2D are less sensitive to miR-451 and, unlike 14-3-3z, are not suppressed by endogenous levels of this miR. To examine whether 14-3-3z was primarily responsible for the impact of miR-451 on cellular behavior, we utilized an RNA-binding antisense oligonucleotide specific for the interaction between miR-451 and the 3 0 -UTR of 14-3-3z (target protector), so as to disrupt only this interaction. We monitored the levels of 14-3-3z, OGT and CDKN2D in cells overexpressing miR-451 or 14-3-3z protector alone, or both combined (Figure 6b ). Overexpression of miR-451 reduced the expression of all three, but the addition of the 14-3-3z protector in miR-451-overexpressing cells restored the basal level and tamoxifen response of only 14-3-3z, reversing the effect of miR-451 overexpression. By contrast, there was no effect of the protector on OGT and CDKN2D with miR-451 overexpression. In cells exposed to 14-3-3z protector alone, there was an increase in the basal (Veh) level of 14-3-3z but no effect on OGT or CDKN2D, as would be expected from reduction in the effect of endogenous miR-451 on 14-3-3z.
We then examined the effect of these perturbations on the growth of Tam R cells (Figure 6c ). As shown previously in Figure 3 , miR-451 knockdown increased 14-3-3z and cell proliferation, whereas miR-451 overexpression suppressed both basal and tamoxifen-stimulated proliferation, and these were restored to the levels in control (Ctrl) cells by co-presence of the 14-3-3z protector (Figure 6c ). The protector alone raised the proliferation rate of Veh-treated cells, consistent with its effect on the endogenous 14-3-3z level, shown in Figure 6b , left panel. Collectively, these results support the hypothesis that the effects of both upand downregulation of miR-451 on cell proliferation and response to tamoxifen are mediated principally by miR-451 regulation of 14-3-3z levels. Our overall findings, schematically depicted in the model in Figure 7 , show that tamoxifen decreases endogenous miR-451, thereby increasing the level of 14-3-3z. 14-3-3z promotes breast cancer cell proliferation, survival and receptor tyrosine kinase (EGFR, HER2) activation, and protein kinase signaling while suppressing apoptosis, all of which support the progression to endocrine resistance.
Discussion
The development of resistance to endocrine therapy is a severe limitation in the treatment of hormone-receptorpositive breast tumors. In this study, we provide evidence for a novel mechanism by which tamoxifen controls 14-3-3z levels through its regulation of the miR, miR-451. It is becoming increasingly clear that miRNAs have a profound impact on many pathological and physiological processes, including proliferation, differentiation and apoptosis (Bartel, 2004; Harfe, 2005) , by dampening the expression of target genes and thereby affording finely tuned cellular regulation. Lowered mRNA levels appear to be the predominant mode of miR regulation, although decreased translational efficiency often contributes to reduced protein output as well (Guo et al., 2010) .
Our previous studies described the upregulation of 14-3-3z by tamoxifen and revealed that high expression of 14-3-3z in primary breast cancers was associated with a poor clinical outcome on tamoxifen (Frasor et al., 2006) . 14-3-3z, which is harbored in a region of frequent genomic gain (8q23), is overexpressed in greater than 40% of breast tumors (Neal et al., 2009) and is overexpressed also in other types of aggressive solid tumors, such as lung cancer . Thus, 14-3-3z has the properties of an oncogene; yet Figure 5 miR-451 and 14-3-3z affect the activation of receptor tyrosine kinases and protein kinases. Immunoblotting for pHer2, pEGFR, pAKT, pMAPK and 14-3-3z in Tam R cells treated with heregulin (HRG) for the minutes indicated after cells were transfected with (a) control or 14-3-3z-expressing polylysine-coated adenovirus or (b) control or pre-miR-451 vector to overexpress miR-451. b-Actin was used as a loading control.
surprisingly, its regulation in breast cancer has been largely unknown. It is of note that the regulation of 14-3-3z and miR-451 is selective for tamoxifen and is not brought about by other ER ligands tested, including the estrogen estradiol or the antiestrogens raloxifene and ICI 182,780, highlighting the remarkable ability of distinct ER-ligand complexes to selectively affect the transcription of specific genes Katzenellenbogen and Katzenellenbogen, 2002; Shang and Brown, 2002; Frasor et al., 2004 Frasor et al., , 2006 . In all cases examined, we observed an inverse relationship between miR-451 and 14-3-3z, implying the importance of this miRNA in the regulation of 14-3-3z. This regulation of miR-451 by tamoxifen was also highly selective, as tamoxifen did not affect the nearby miR-144. The differential regulation of miR-451 and 14-3-3z by tamoxifen vs raloxifene is reminiscent of other differences also observed by us previously when genome-wide gene expression comparison analyses of these two SERMs were performed (Frasor et al., 2004) . These differential effects of the two SERMs in regulation of miR-451 and 14-3-3z may underlie some differences in their activities observed in the STAR (Study of Tamoxifen and Raloxifene) breast cancer prevention trial (Dunn and Ford, 2001; Vogel et al., 2006 Vogel et al., , 2010 .
Previous reports have noted that miR-451 is very highly conserved among vertebrates, and that its maturation is independent of Dicer (Yang et al., 2010) . Moreover, miR-451 has been shown recently to have a crucial role in erythrocyte differentiation by targeting 14-3-3z (Masaki et al., 2007; Dore et al., 2008; Patrick et al., 2010; Yu et al., 2010) . Expression of miR-451 has also been detected in normal gastric mucosa and found to be decreased in gastric cancer (Bandres et al., 2009) . These findings imply that miR-451 is required for the development and maintenance of normal tissues (Williams et al., 2007) and may be downregulated during the progression to cancer. Of note, we found that our less-aggressive cell line (MCF7) showed higher expression of miR-451 compared with the moreaggressive tamoxifen-resistant cell line. We have also observed upregulation of 14-3-3z and downregulation of miR-451 by tamoxifen in ER-positive, HER2-positive BT474 cells (data not presented). Therefore, the loss of miR-451 induced by Tam treatment appears to be an Figure 7 Schematic representation of the effect of tamoxifen on miR-451 and 14-3-3z regulation and their impact on breast cancer cell phenotypic properties leading to tamoxifen resistance. Tamoxifen downregulates miR-451, resulting in the upregulation of 14-3-3z, with consequent increased receptor tyrosine kinase signaling, increased cell proliferation and colony formation, and reduced apoptosis, thereby leading to tamoxifen resistance.
underlying mechanism by which ER-positive breast cancer cells become resistant to tamoxifen therapy by upregulation of 14-3-3z. As supporting evidence for this, we show that reduction of miR-451 by tamoxifen treatment or knockdown of miR-451 by a specific antagomir increased 14-3-3z and cell survival, whereas increasing miR-451 could resensitize Tam R cells to SERMs, as observed by the decrease in cell viability and suppression of anchorage-independent growth that correlated with increased apoptosis and reduced EGFR, HER2 and MAPK signaling in tamoxifen-treated miR-451-overexpressing cells. This sensitization of tamoxifen-resistant cells to the growth-inhibitory effects of Tam and other antiestrogens by increased expression of miR-451 suggests that restoration of expression of this miRNA in endocrine therapy-resistant cancer cells might have important implications for effective breast cancer treatment.
In summary, we document miR-451 to be a potent suppressor of the progression to tamoxifen resistance through its ability to target 14-3-3z, a key proliferative and antiapoptotic factor in breast cancer. Modulation of miR-451 status impacted growth, apoptosis, receptor tyrosine kinase activity and sensitivity to SERMs. We identify miR-451 as a target of the ER-tamoxifen complex and show an inverse correlation between cellular miR-451 and 14-3-3z levels. Collectively, these data imply that increasing the level of miR-451 may have beneficial therapeutic effects in the large proportion of breast cancers expressing high levels of 14-3-3z. Progress in miR-directed therapeutic approaches (Lowery et al., 2008; Shan et al., 2008) offers hope that such strategies might prove useful in reversing endocrine resistance and reducing breast cancer recurrence.
Materials and methods
Cell cultures, constructs and cell transfections MCF7 cells, obtained from the American Type Culture Collection (Manassas, VA, USA) and tamoxifen-resistant MCF7 cells (Tam R cells) described previously (Herman and Katzenellenbogen, 1996) , were cultured in MEM (Sigma-Aldrich Corp., St Louis, MO, USA), supplemented with 5% calf serum (HyClone, Logan, UT, USA), 100 mg/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) and 25 mg/ml gentamicin (Invitrogen). Four days before control Veh or ligand treatments, cells were seeded in phenol red-free MEM containing 5% charcoal-dextran-treated calf serum. The medium was changed on day 2 and 4 of culture before treatments. Pri-miRNA-451 was purchased from Origene (Rockville, MD, USA) and antagomiR-451, antagomiR-144 and negative control antagomiRs were purchased from Applied Biosystems (Carlsbad, CA, USA). A 40-nt single-stranded RNA-binding antisense oligonucleotide specific for the interaction between miR-451 and the 3 0 -UTR of 14-3-3z (target protector) was purchased from Qiagen (Valencia, CA, USA). siRNA targeting ERa was as described previously (Chang et al., 2008) . Ectopic overexpression of 14-3-3z used lysine-coated adenovirus or control adenovirus (Allgood et al., 1997) . Cell transfections were performed with Fugene 6 (Roche) or Dharmafect (Dharmacon, Lafayette, CO, USA).
RT-PCR and quantitative PCR
Total RNA was isolated from cells using TRIzol (Invitrogen), RNA samples were reverse transcribed by SuperScript II reverse transcriptase (Invitrogen) and real-time PCR was carried out on the ABI Prism 7900HT using SYBR Green PCR Master Mix (Applied Biosystems) as described previously (Frasor et al., 2006) .
Western blot analysis
Whole-cell extracts were prepared using 1X RIPA lysis buffer (Upstate/Chemicon, Temecula, CA, USA) supplemented with 1 Â complete protease inhibitor (Roche, Basel, Switzerland). Proteins were separated on 15% SDS-PAGE gels and transferred to nitrocellulose membranes. Western blotting used antibodies against 14-3-3z (Santa Cruz Biotechnology, Santa Cruz, CA, USA), b-actin (Sigma-Aldrich Corp), pEGFR, pHER2, pMAPK and pAKT (Cell Signaling, Danvers, MA, USA).
Cell proliferation assays
WST-1 assay (Roche, Basel, Switzerland) was used to quantify cell viability. Absorbance was measured at 450 nm using a BioRad 680 Microplate Reader (BioRad, Hercules, CA, USA), and all assays were performed in triplicate.
Apoptosis assays
Apoptosis was measured based on DNA content and analyzed by flow cytometry using BD-FACS Canto. Cells were fixed in 70% ethanol, stained for 30 min with 20 mg/ml propidium iodide (PI, Molecular Probe, Carlsbad, CA, USA) in Triton-X (Sigma) in the presence of DNAse-free RNAse A (Sigma), and PI staining was measured as previously reported (Riccardi and Nicoletti, 2006) .
Soft-agar colony formation assays A 1.5-ml base layer of agar (0.5% agar in phenol red-free Dulbecco's Modified Eagle Medium (DMEM) with 5% charcoal stripped-FCS) was allowed to solidify in a six-well flat-bottomed plate before the addition of 1.5 ml of cell suspensions containing 4000 cells in 0.35% agar in phenol redfree DMEM with 5% charcoal-stripped FCS. The cell-containing layer was then solidified at 4 1C for 20 min. Colonies were allowed to grow for 13 days at 37 1C before imaging.
